Detalles de la búsqueda
1.
Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of Panobinostat in Combination with Bortezomib and Dexamethasone in Japanese Patients with Relapsed or Relapsed-and-Refractory Multiple Myeloma.
Acta Haematol
; 144(3): 264-274, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33279887
2.
Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma.
Ann Hematol
; 99(5): 1063-1072, 2020 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-32248251
3.
Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma.
Ann Hematol
; 98(7): 1703-1711, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31049648
4.
Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries.
Ann Hematol
; 98(4): 941-949, 2019 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-30729281
5.
Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Lancet Oncol
; 19(3): 370-381, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29429912
6.
Unsuppressed serum albumin levels may jeopardize the clinical relevance of the international staging system to patients with light chain myeloma.
Hematol Oncol
; 36(5): 792-800, 2018 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-30176173
7.
Rapid Prediction of Bacterial Heterotrophic Fluxomics Using Machine Learning and Constraint Programming.
PLoS Comput Biol
; 12(4): e1004838, 2016 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-27092947
8.
International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma.
Lancet Oncol
; 17(8): e328-e346, 2016 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27511158
9.
Reduced frequency treatment with bortezomib plus dexamethasone for elderly patients with relapsed and/or refractory multiple myeloma: a phase 2 study of the Japanese Myeloma Study Group (JMSG-0902).
Ann Hematol
; 95(6): 921-9, 2016 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-27044390
10.
Primary Plasma Cell Leukemia in the Era of Novel Agents: A Multicenter Study of the Japanese Society of Myeloma.
Acta Haematol
; 135(2): 113-21, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-26505781
11.
Patients assigned to VGPR, PR, and SD in the IMWG response category are composed of heterogeneous population when assessed by the heavy/light chain assay.
Hematol Oncol
; 37(3): 316-318, 2019 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-30938836
12.
Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study.
Am J Hematol
; 89(7): 751-6, 2014 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-24723430
13.
Survival of multiple myeloma patients aged 65-70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the Japanese Society of Myeloma and the European Myeloma Network.
Acta Haematol
; 132(2): 211-9, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24662986
14.
Effect of acidic condition on the metabolic regulation of Escherichia coli and its phoB mutant.
Arch Microbiol
; 195(3): 161-71, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23274360
15.
Feedback regulation and coordination of the main metabolism for bacterial growth and metabolic engineering for amino acid fermentation.
Biotechnol Adv
; 55: 107887, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-34921951
16.
Switching nanoprecipitates to resist hydrogen embrittlement in high-strength aluminum alloys.
Nat Commun
; 13(1): 6860, 2022 Nov 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-36400773
17.
Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval.
J Bone Oncol
; 33: 100416, 2022 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-35242510
18.
Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma.
J Cancer Res Clin Oncol
; 148(1): 191-203, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34080068
19.
Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: A multicenter retrospective study in Japan.
EJHaem
; 3(3): 838-848, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36051061
20.
Risk of Japanese carriers of hyperphosphorylated paratarg-7, the first autosomal-dominantly inherited risk factor for hematological neoplasms, to develop monoclonal gammopathy of undetermined significance and multiple myeloma.
Cancer Sci
; 102(3): 565-8, 2011 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-21205072